Delamanid may be beneficial as an add-on therapy to the standard treatment regimen of multidrug resistant tuberculosis

The investigational antibiotic delamanid increased 2-month sputum-culture conversion in patients with multidrug-resistant pulmonary tuberculosis (TB). This was the main finding of a recent randomized, placebo-controlled trial that sought to determine the efficacy and safety of delamanid added to standard therapy vs standard therapy alone in this population.

Key Point: Delamanid, a new antibiotic with activity in patients with multidrug-resistant tuberculosis (TB), was superior to placebo when added to standard TB regimens in 2-month sputum-culture conversion. The incidence of QTc prolongation was increased in both delamanid groups compared with placebo, although none of the cases progressed clinically.

According to the World health Organization (WHO), TB is a major public health concern in India. One-fifth of global TB cases are from India, which amounts to 2 million people in India with TB annually. India was also the third country in the world in which a completely drug-resistant strain had been identified.

A total of 481 patients from 17 countries were randomized to receive either delamanid 100 mg twice daily, delamanid 200 mg twice daily, or placebo, all in addition to standard TB therapy according to WHO guidelines. Delamanid is a...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Infectious Disease, Pharmacology, Primary Care and tagged , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.